An inhibitor of wild-type and mutant Bcr-Abl (IC50s 15 and 9-400 nM respectively) selective for wild-type and mutant Bcr-Abl over Src and LYN (IC50s 5000 nM for both) inhibits Bcr-Abl autophosphorylation and cell proliferation in Ba/F3 cells expressing wild-type or mutant Bcr-Abl (IC50s 7-155 and 13-51 nM respectively) reduces midbrain Bcr-Abl autophosphorylation amyloid-B levels and neuronal loss as well as improves autophagosome clearance and reverses cognitive deficits in the Tg2576 transgenic mouse model of Alzheimers disease at 1 mg/kg reduces serum creatine levels renal profibrotic gene expression and tubulointerstitial damage as well as increases survival in a rat model of 5/6 nephrectomy-induced chronic kidney disease